SOURCE: Entest BioMedical Inc.

March 15, 2010 08:00 ET

Entest BioMedical Announces It Is Developing a Bioinformatics Model for COPD

Company Aims to Integrate Existing Molecular Knowledge of COPD to Aid Its Development of Its Stem Cell / Photoceutical Therapy for COPD

SAN DIEGO, CA--(Marketwire - March 15, 2010) -  Entest BioMedical Inc. (OTCBB: ENTB) announced today It is creating a bioinformatics-based program combining advances in molecular knowledge of Chronic Obstructive Pulmonary Disease (COPD) with computer-powered search tools to integrate existing and newly generated data for this condition. Bioinformatics is defined as the collection, classification, storage, and analysis of biochemical and biological information using computers especially as applied in molecular genetics and genomics. One of the best known applications of bioinformatics methods is the Human Genome Project.

"While there are many pieces to the puzzle of COPD, the majority of research today is focused on finding new pieces as opposed to making sense of the pieces we already have," said Dr. Feng Lin, Scientific Director of Entest. "We have begun a Program based on using various automated algorithms to mine existing data sets and develop hypotheses that can be experimentally tested."

One of the initial tasks of the program is the creation of databases containing all genes associated with various aspects of COPD. These genes will then categorized based on biological functionality and association with each other. Once a global perspective of the genes and how their functions inter-relate is achieved, examination can be made as to which existing drugs may act somewhere on the pathway and possibility induce a benefit.

"By assembling everything known in the literature regarding COPD at a molecular level, our scientists will have an overall understanding of this terrible disease," said David Koos. "In addition, the bioinformatics approach will allow Entest to develop new intellectual property, some of which we anticipate will include new uses of existing drugs on the market."

The basis for the current program originates from internal Entest discussions involving the need for appropriate biomarkers for planned photoceutical trials. Given that the mechanism of action of photoceuticals is still relatively unclear, clinical trials will require sensitive biomarkers, which to some extent are not available in COPD. It is anticipated that the bioinformatics program will be of benefit in this aspect. 

The Company will be hosting another interview with Its Chairman & CEO on Wednesday morning at 11 a.m. PDT at Mr. Koos will discuss the importance of this new bioinformatics approach on strengthening Its COPD treatment model.

About Entest BioMedical Inc.:

Entest BioMedical Inc. (OTCBB: ENTB) is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), immuno-cancer therapies, testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation). ENT - 576™ is a proprietary laser device currently under development by Entest. The Company has filed 3 patent applications relating to the treatment of COPD. Entest Biomedical, Inc. is a majority owned subsidiary of Bio-Matrix Scientific Group Inc. (OTCBB: BMSN). Recently Entest published in the peer reviewed literature its platform technology, which is available at

About Bio-Matrix Scientific Group:

Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) is a biotechnology company headquartered in San Diego, Ca. with a 15,000 sq. ft. facility that houses two secure cryogenic stem cell banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories. David Koos serves as Chairman & CEO concurrently for BMSN and ENTB.

Forward-looking statements:

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Contact Information